Furthermore, a recent investigation utilizing the most up-to-date records from the United States Food and Drug Administration’s Adverse Event Reporting System has indicated a potential link between SGLT2i and the development of AKI, although this association may be mitigated in instances where renin-angiotensin-aldosterone system inhibitors (RAASi), such as angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB), are concurrently administered (Katsuhara and Ikeda, 2021). This evidence concerns the gene REN and acute kidney injury.